Use of Bayesian Methodology in Clinical Trials of Drug and Biological Products: Draft Guidance for Industry
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
January 9, 2026
January 12, 2026
8e9c345e-0994-47b3-8d6c-054f04ed937e
Related Documents
Master Protocols for Drug and Biological Product Development
Guidance DocumentDecember 21, 2023Center for Drug Evaluation and Research
Meta-Analyses of Randomized Controlled Clinical Trials to Evaluate the Safety of Human Drugs or Biological Products
Guidance DocumentNovember 7, 2018Center for Drug Evaluation and Research
Nonproprietary Naming of Biological Products: Update Guidance for Industry
Guidance DocumentMarch 8, 2019Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox